Smart People: Jeff Elton
How did the pandemic impact oncology trials? What kept them moving during lockdowns?
Oncology care was uniquely, negatively impacted by COVID-19. In the early days of the pandemic, oncology trials that were open either stopped enrolling patients or were substantially slowed, and new study starts were delayed. There were also delayed diagnoses of new patients due to the pandemic. Obviously, fewer patients being diagnosed means fewer prospective patients who may consider clinical trials. It also means that patients’ cancers will progress and that they’ll start treatment at more advanced stages.
That situation persisted from late February 2020 through the middle of the summer of 2020, when precautions had been fully integrated into practice. The standard-of-care was modified to be protective of patients and staff. In certain cancers, surgical interventions were limited in favour of less invasive initial treatment approaches or medical-only treatment. L
Impact of proposed law would increase regulatory oversight of certain diagnostic tests
Legislation currently under consideration in the U.S. Congress would increase regulatory oversight of certain diagnostic tests, and a new study by researchers at Massachusetts General Hospital (MGH) and colleagues from several other institutions demonstrates that its potential impact will depend on key details in the bill s final language.
This study, published in
JCO Oncology Practice, offers the first evidence-based analysis of how new rules proposed for the regulation of laboratory-developed tests (LDTs) could affect health care costs in the United States.
The idea of having more oversight of LDTs is justified. But our results show that it s very important to align the language in this new law with the intent of what it s trying to accomplish.
MCED is an emerging set of technologies that, when added to existing single cancer screening, provides an opportunity to identify a broad range of cancers earlier in the course of disease. With the use of a simple blood draw, urine, saliva, or stool sample test, MCED technology enables clinicians to rapidly screen for multiple types of cancer at once, potentially catching and treating them earlier. Multi-cancer early detection represents a paradigm shift in how cancers will be diagnosed and treated in the future, said Brian Druker, MD, director of the Knight Cancer Institute at Oregon Health & Science University, and a founding member of the MCED forum. By bringing together this group of experts from across the cancer research, clinical, and patient advocacy landscapes, we intend to evaluate evidence and establish standards for the emerging field of MCED that can guide physicians in adopting the technology in clinical practice. Ultimately, we are united in our mission to evaluate
Scandion Oncology engages former ASCO executive as clinical advisor
Scandion Oncology is pleased to announce that we have appointed Dr. Richard L. Schilsky, a seasoned and highly profiled international leader as a member of our clinical advisory board (CAB). Dr. Schilsky is the former CMO and Executive Vice President of the American Society of Clinical Oncology (ASCO) and a long-time faculty member of the University of Chicago.
Scandion Oncology A/S
Publicerad: 21 april 2021, 11:30
Copenhagen, April 21, 2021. Scandion Oncology, The Cancer Drug Resistance Company, is pleased to announce that
Richard L. Schilsky, MD, FACP, FSCT, FASCO has accepted to join the clinical advisory board of Scandion Oncology.
POLITICO
Get the Prescription Pulse newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presented by Gilead Sciences, Inc.
With Emily Martin and Brianna Ehley
On Tap
with a targeted strategy based on HIV lessons. Johnson & Johnson and Merck set for Biden meeting
on Wednesday to discuss Covid-19 vaccines. Six million tests are being administered a day